The fact that NaW treatment affects glycogen metabolism in renal proximal tubules in IRS2-KO mice, similar to glycogen storage disease type 1a [29], turns on a red light on its potential use as a drug for type 2 diabetes treatment. The gene discussed is IRS2; the disease is type 2 diabetes mellitus.